Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...

We recently published a list of Why These 15 Defensive Stocks Are Surging In 2025. In this article, we are going to take a ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...

The latest trading session saw Hims & Hers Health, Inc. (HIMS) ending at $37.04, denoting a -0.99% adjustment from its last day's close. This change lagged the S&P 500's daily gain of 0.16%. At the ...

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

Learn more about whether Hims & Hers Health, Inc. or LifeStance Health Group, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Alignment Healthcare, Inc. or Hims & Hers Health, Inc. is a better investment based on AAII's A+ ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...